Stocks / REGN / Total Debt

Regeneron Pharmaceuticals, Inc. Total Debt 2008–2025

Regeneron Pharmaceuticals, Inc. reported $1.99B of total debt (short- plus long-term borrowings) for fiscal 2025. That was 0.1% higher than fiscal 2024. Compared with fiscal 2020, the change was +0.4%.

Latest filed value
$1.99B
One-year change
+0.1%
Change since 2020
+0.4%
Latest period end
2025
Regeneron Pharmaceuticals, Inc. Total Debt history from 2008 to 2025FY 2008: 0FY 2009: 0FY 2010: 0FY 2011: 0FY 2012: 0FY 2013: 0FY 2014: 0FY 2015: 0FY 2016: 0FY 2017: 0FY 2018: 0FY 2019: 0FY 2020: 1978500000FY 2021: 1980000000FY 2022: 1981400000FY 2023: 1982900000FY 2024: 1984400000FY 2025: 1985900000
Annual filed history. Hover chart points for raw values; the accessible table below is the source of record.
Fiscal yearTotal DebtChange (YoY)
FY 2025$1.99B+0.1%
FY 2024$1.98B+0.1%
FY 2023$1.98B+0.1%
FY 2022$1.98B+0.1%
FY 2021$1.98B+0.1%
FY 2020$1.98B
FY 2019$0
FY 2018$0
FY 2017$0
FY 2016$0
FY 2015$0
FY 2014$0
FY 2013$0
FY 2012$0
FY 2011$0
FY 2010$0
FY 2009$0
FY 2008$0

Source: Regeneron Pharmaceuticals, Inc. SEC filings — balance sheet (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open REGN 10-K filings at SEC EDGAR · Methodology · Download CSV.

How to read this history

Regeneron Pharmaceuticals, Inc. reported $1.99B of total debt (short- plus long-term borrowings) for fiscal 2025. That was 0.1% higher than fiscal 2024. Compared with fiscal 2020, the change was +0.4%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.

Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.

See the full picture for Regeneron Pharmaceuticals, Inc.

Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.

Open the interactive view — free

Regeneron Pharmaceuticals, Inc. — frequently asked questions

What is Regeneron Pharmaceuticals, Inc.'s total debt (short- plus long-term borrowings)?

Regeneron Pharmaceuticals, Inc. (REGN) reported total debt (short- plus long-term borrowings) of $1.99B for fiscal year 2025, per its SEC filings.

Where does this data come from?

Figures are computed from Regeneron Pharmaceuticals, Inc.'s official SEC filings (balance sheet (10-K)), refreshed nightly. Not investment advice.

More REGN financial history

Full REGN fundamentals page → · Analyze total debt (short- plus long-term borrowings) with a free tool → · All 1,500+ companies →